GALECTIN THERAPEUTICS INC
NORCROSS, GA · CIK 0001133416 · Biotech · Private
Small molecule therapeutics targeting galectin-3 to treat metabolic dysfunction-associated fatty liver disease (MASH)
galectintherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $6.8M
- 4 Form D · Jan 2017
- 117 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 12 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20102011201220132014201520162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,250,000 | |
| Private capital raised | Form D · SEC | $1,500,000 | |
| Private capital raised | Form D · SEC | $3,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2456 | Prolific Machines | — | $55M |
| 2457 | LIFESPLICE PHARMA, LLC | — | — |
| 2458 | ImmusanT, Inc. | — | $33M |
| 2459 | GALECTIN THERAPEUTICS INC | — | $6.8M |
| 2460 | Eidos Therapeutics | — | $26M |
| 2461 | Expesicor Inc | — | — |
| 2462 | Actym Therapeutics, Inc. | — | $25M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gilbert AmelioDirector
- Jack CallicuttDirector · Executive Officer
- James CzirrDirector · Executive Officer
- Maureen FoleyExecutive Officer
- Kevin FreemanDirector
- Arthur GreenbergDirector
- Anatole KlyosovExecutive Officer
- Rod MartinDirector
- John MauldinDirector
- S. NeillDirector
- Gilbert OmennDirector
- Steven PrelackDirector
- Jerald RomeDirector
- Marc RubinDirector
- Harold ShlevinExecutive Officer
- Anthony SquegliaExecutive Officer
- Peter TraberDirector · Executive Officer
- Eliezer ZomerExecutive Officer
- Theodore ZucconiDirector · Executive Officer
- Theodore ZuconniDirector
Patents
- Composition Of Novel Carbohydrate Drug For Treatment Of Human Diseasesapplication
- Composition Of Novel Carbohydrate Drug For Treatment Of Human Diseasesapplication
- Methods For Treatment Of Arthritisgranted
- Compositions Comprising Galactose-Pronged Polysaccharidesapplication
- Composition of Novel Carbohydrate Drug for Treatment of Human Diseasesgranted
- Galactose-pronged Polysaccharides In A Formulation For Antifibrotic Therapiesgranted
- Composition Of Novel Carbohydrate Drug For Treatment Of Human Diseasesgranted
- Composition Of Novel Carbohydrate Drug For Treatment Of Human Diseasesgranted
- Method For Treatment Of Pulmonary Fibrosisgranted
- Galacto-rhamnogalacturonate Compositions For The Treatment Of Diseases Associated With Elevated Inducible Nitric Oxide Synthasegranted
- Composition Of Novel Carbohydrate Drug For Treatment Of Human Diseasesgranted
- Method for treatment of pulmonary fibrosisgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.